scholarly journals Human Lung Microbiome on the Way to Cancer

2019 ◽  
Vol 2019 ◽  
pp. 1-6 ◽  
Author(s):  
Olga V. Kovaleva ◽  
Daniil Romashin ◽  
Irina B. Zborovskaya ◽  
Mikhail M. Davydov ◽  
Murat S. Shogenov ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Helicobacter Pylori ◽  
Tumor Progression ◽  
Microbial Communities ◽  
Cancer Progression ◽  
Human Lung ◽  
Lung Microbiome ◽  
Long Time ◽  
Underlying Mechanisms ◽  
Proinflammatory Factors

Recent research on cancer-associated microbial communities led to the accumulation of data on the interplay between bacteria, immune and tumor cells, the pathways of bacterial induction of carcinogenesis, and its meaningfulness for medicine. Microbial communities that have any kind of impact on tumor progression and microorganisms associated with tumors have been defined as oncobiome. Over the last decades, a number of studies were dedicated to Helicobacter pylori and its role in the progression of stomach tumors, so this correlation can be regarded as proven. Involvement of bacteria in the induction of lung cancer has been largely ignored for a long time, though some correlations between this type of cancer and lung microbiome were established. Despite the fact that in the present the microbial impact on lung cancer progression has many confirmations, the underlying mechanisms are poorly understood. Microorganisms can contribute to tumor initiation and progression through production of bacteriotoxins and other proinflammatory factors. The purpose of this review is to organize the available data on lung cancer microbiome and its role in malignant tumor progression.

scholarly journals Human Puf-A, a Novel Component of 90S Pre-ribosome, Links Ribosome Biogenesis to Cancer Progression

2018 ◽  
Author(s):  
Huan-Chieh Cho ◽  
Yenlin Huang ◽  
Jung-Tung Hung ◽  
Li-Chun Lai ◽  
Sheng-Hung Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tumor Progression ◽  
Cancer Progression ◽  
Ribosome Biogenesis ◽  
Human Lung ◽  
Cell Cycle Checkpoints ◽  
Human Lung Cancer ◽  
P53 Expression ◽  
Stage I Lung Cancer ◽  
Transcriptional Target

AbstractWe describe a novel biogenesis factor of the 90S pre-ribosome, Puf-A, which is a negative transcriptional target of p53. The expression of Puf-A is not only upregulated in advanced human lung cancer and tumors of patients especially with TP53 mutation, but also is highly prognostic for stage I lung cancer. Loss of Puf-A expression prevents KrasG12D/p53-/-–induced tumor progression in the lungs and induces apoptosis in TP53– mutated cancers and c-Myc/p53-/-–transformed cells as well. Overexpression of Puf-A enhances proliferation of normal cells after c-Myc induction and overcomes the cell-cycle checkpoints incurred by p53 expression. Mechanistically, Puf-A interacts with double-stranded structures of the 5.8S sequence within pre-rRNA and maintains the integrity of 90S pre-ribosomes, thereby impacting early ribosome assembly and export of ribosomes from nuclei. Silencing of Puf-A disrupts the assembly of 90S pre-ribosomes and induces the translocation of its associated nucleophosmin (NPM1) from nucleoli to the nucleoplasm, resulting in impairment of ribosome synthesis. Thus, Puf-A is crucial for over-activation of ribosome biogenesis and contributes to tumor progression and cancer growth.

scholarly journals POU2F2 promotes the proliferation and motility of lung cancer cells by activating AGO1

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Ronggang Luo ◽  
Yi Zhuo ◽  
Quan Du ◽  
Rendong Xiao
Keyword(s):  
Lung Cancer ◽  
Tumor Growth ◽  
Cancer Cells ◽  
Cancer Progression ◽  
Human Lung ◽  
Lung Cancer Cells ◽  
Human Lung Cancer ◽  
Cancer Tissues

Abstract Background To detect and investigate the expression of POU domain class 2 transcription factor 2 (POU2F2) in human lung cancer tissues, its role in lung cancer progression, and the potential mechanisms. Methods Immunohistochemical (IHC) assays were conducted to assess the expression of POU2F2 in human lung cancer tissues. Immunoblot assays were performed to assess the expression levels of POU2F2 in human lung cancer tissues and cell lines. CCK-8, colony formation, and transwell-migration/invasion assays were conducted to detect the effects of POU2F2 and AGO1 on the proliferaion and motility of A549 and H1299 cells in vitro. CHIP and luciferase assays were performed for the mechanism study. A tumor xenotransplantation model was used to detect the effects of POU2F2 on tumor growth in vivo. Results We found POU2F2 was highly expressed in human lung cancer tissues and cell lines, and associated with the lung cancer patients’ prognosis and clinical features. POU2F2 promoted the proliferation, and motility of lung cancer cells via targeting AGO1 in vitro. Additionally, POU2F2 promoted tumor growth of lung cancer cells via AGO1 in vivo. Conclusion We found POU2F2 was highly expressed in lung cancer cells and confirmed the involvement of POU2F2 in lung cancer progression, and thought POU2F2 could act as a potential therapeutic target for lung cancer.

scholarly journals Radiation-Enhanced Lung Cancer Progression in a Transgenic Mouse Model of Lung Cancer Is Predictive of Outcomes in Human Lung and Breast Cancer

2014 ◽  
Vol 20 (6) ◽  
pp. 1610-1622 ◽  
Author(s):  
Oliver Delgado ◽  
Kimberly G. Batten ◽  
James A. Richardson ◽  
Xian-Jin Xie ◽  
Adi F. Gazdar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Mouse Model ◽  
Transgenic Mouse ◽  
Cancer Progression ◽  
Human Lung ◽  
Transgenic Mouse Model

scholarly journals Microbiome dysbiosis in lung cancer: from composition to therapy

2020 ◽  
Vol 4 (1) ◽  
Author(s):  
Ning-Ning Liu ◽  
Qiang Ma ◽  
Yang Ge ◽  
Cheng-Xiang Yi ◽  
Lu-Qi Wei ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Progression ◽  
Tumor Development ◽  
Disease Status ◽  
Specific Pattern ◽  
Current Status ◽  
Healthy Human ◽  
Human Lungs ◽  
Underlying Mechanisms

AbstractThe correlations between microbiota dysbiosis and cancer have gained extensive attention and been widely explored. As a leading cancer diagnosis worldwide, lung cancer poses a great threat to human health. The healthy human lungs are consistently exposed to external environment and harbor a specific pattern of microbiota, sharing many key pathological and physiological characteristics with the intestinal tract. Although previous findings uncovered the critical roles of microbiota in tumorigenesis and response to anticancer therapy, most of them were focused on the intestinal microbiota rather than lung microbiota. Notably, the considerable functions of microbiota in maintaining lung homeostasis should not be neglected as the microbiome dysbiosis may promote tumor development and progression through production of cytokines and toxins and multiple other pathways. Despite the fact that increasing studies have revealed the effect of microbiome on the induction of lung cancer and different disease status, the underlying mechanisms and potential therapeutic strategies remained unclear. Herein, we summarized the recent progresses about microbiome in lung cancer and further discussed the role of microbial communities in promoting lung cancer progression and the current status of therapeutic approaches targeting microbiome to alleviate and even cure lung cancer.

scholarly journals Sulfiredoxin-Peroxiredoxin IV axis promotes human lung cancer progression through modulation of specific phosphokinase signaling

2011 ◽  
Vol 108 (17) ◽  
pp. 7004-7009 ◽  
Author(s):  
Q. Wei ◽  
H. Jiang ◽  
Z. Xiao ◽  
A. Baker ◽  
M. R. Young ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Progression ◽  
Human Lung ◽  
Human Lung Cancer

TLR9 Signaling Promotes Tumor Progression of Human Lung Cancer Cell In Vivo

2009 ◽  
Vol 15 (4) ◽  
pp. 623-630 ◽  
Author(s):  
Tao Ren ◽  
Lin Xu ◽  
Shuxian Jiao ◽  
Yanying Wang ◽  
Yingyun Cai ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tumor Progression ◽  
Cancer Cell ◽  
Human Lung ◽  
Human Lung Cancer ◽  
Lung Cancer Cell ◽  
Human Lung Cancer Cell ◽  
Tlr9 Signaling

scholarly journals Metabolic Reprogramming of Cancer Cells during Tumor Progression and Metastasis

Metabolites ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 28
Author(s):  
Kenji Ohshima ◽  
Eiichi Morii
Keyword(s):  
Oxidative Stress ◽  
Tumor Progression ◽  
Cancer Cells ◽  
Cancer Progression ◽  
Treatment Strategies ◽  
Primary Site ◽  
Metabolic Reprogramming ◽  
Cancer Growth ◽  
Anchorage Independent Growth ◽  
Underlying Mechanisms

Cancer cells face various metabolic challenges during tumor progression, including growth in the nutrient-altered and oxygen-deficient microenvironment of the primary site, intravasation into vessels where anchorage-independent growth is required, and colonization of distant organs where the environment is distinct from that of the primary site. Thus, cancer cells must reprogram their metabolic state in every step of cancer progression. Metabolic reprogramming is now recognized as a hallmark of cancer cells and supports cancer growth. Elucidating the underlying mechanisms of metabolic reprogramming in cancer cells may help identifying cancer targets and treatment strategies. This review summarizes our current understanding of metabolic reprogramming during cancer progression and metastasis, including cancer cell adaptation to the tumor microenvironment, defense against oxidative stress during anchorage-independent growth in vessels, and metabolic reprogramming during metastasis.

scholarly journals Lung microbiome alterations in NSCLC patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Leliang Zheng ◽  
Ruizheng Sun ◽  
Yinghong Zhu ◽  
Zheng Li ◽  
Xiaoling She ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Progression ◽  
Rare Species ◽  
Common Species ◽  
Oral Microbiota ◽  
Metagenomic Sequencing ◽  
Microbial Composition ◽  
Lung Microbiome ◽  
Egfr Expression ◽  
Nsclc Patients

AbstractLung is colonized by a diverse array of microbes and the lung microbiota is profoundly involved in the development of respiratory diseases. There is little knowledge about the role of lung microbiota dysbiosis in lung cancer. In this study, we performed metagenomic sequencing on bronchoalveolar lavage (BAL) from two different sampling methods in non-small cell lung cancer (NSCLC) patients and non-cancer controls. We found the obvious variation between bronchoscopy samples and lobectomy samples. Oral taxa can be found in both bronchoscopy and lobectomy samples and higher abundance of oral taxa can be found in bronchoscopy samples. Although the NSCLC patients had similar microbial communities with non-cancer controls, rare species such as Lactobacillus rossiae, Bacteroides pyogenes, Paenibacillus odorifer, Pseudomonas entomophila, Magnetospirillum gryphiswaldense, fungus Chaetomium globosum et al. showed obvious difference between NSCLC patients and non-cancer controls. Age-, gender-, and smoking-specific species and EGFR expression-related species in NSCLC patients were detected. There results implicated that different lung segments have differential lung microbiome composition. The oral taxa are found in the lobectomy samples suggesting that oral microbiota are the true members of lung microbiota, rather than contamination during bronchoscopy. Lung cancer does not obviously alter the global microbial composition, while rare species are altered more than common species. Certain microbes may be associated with lung cancer progression.

Sign in / Sign up

Export Citation Format

Share Document